Article thumbnail

Should patents for antiretrovirals be waived in the developing world? Annual varsity medical debate - London, 21 January 2011

By Fenella Corrick, Robert Watson and Sanjay Budhdeo

Abstract

The 2011 Varsity Medical Debate, between Oxford and Cambridge Universities, brought students and faculty together to discuss the waiving of patents for antiretroviral therapies in the developing world. With an estimated 29.5 million infected by Human Immunodeficiency Virus (HIV) in low- and middle-income countries and only 5.3 million of those being treated, the effective and equitable distribution of anti-retroviral therapy (ART) is an issue of great importance. The debate centred around three areas of contention. Firstly, there was disagreement about whether patents were the real barrier to the access of anti-retroviral therapy in the developing world. Secondly, there were differing views on the effectiveness of a patent pool. Thirdly, concerns were raised over the impact of waiving patents on research to produce new and better anti retro-viral drugs

Topics: Meeting Report
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3160882
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2002). do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. Aids
  2. Doctors of the World poster.
  3. (2008). EK: Improving Access to HIV/AIDS Medicines in Africa: Trade-Related Aspects of Intellectual Property Rights Flexibilities.
  4. (2001). Experts clash over likely impact of cheap AIDS drugs in Africa. Nature
  5. (2008). Frontiers: Affordability, Availability and Adaptability of AIDS Drugs in Developing Countries: An Ongoing Challenge.
  6. (2001). Gillespie-White L: Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?
  7. (2009). Institute of Medicine: Breakthrough business models: drug development for rare and neglected diseases and individualized therapies: workshop summary. National Academies Press: Washington D. C.;
  8. (2010). Joint Programme on HIV/AIDS Global Report:
  9. (2010). Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care.
  10. (2008). Schackman BR: The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc
  11. (2010). Technology Development Through Pooling ARV Drug Patents: A Vision from China.
  12. The Access To Medicine Foundation.
  13. The Bill and Melinda Gates Foundation.
  14. The Health Impact Fund: boosting pharmaceutical innovation without obstructing free access.
  15. (2007). The Political Economy of AIDS Treatment: Intellectual Property and the Transformation of Generic Supply. International Studies Quarterly
  16. (2006). VV: Estimating the cost of new drug development: Is it really $802 million? Health Affairs